drugset / Trial / NCT04365985
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
RandomizedFactorialTriple-blindTreatment
Summary
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.
Timeline
- Start
- 2020-04-29
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.15 mg/kg | Intravenous |
| Subject | Ketamine | Small molecule | 0.3 mg/kg | Intravenous |
| Subject | Naltrexone | Small molecule | 4.5 mg | Oral |